Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus.
In this study the kinetics of humoral and cellular immune responses in first-time vaccinees and re-vaccinees with the yellow fever 17DD vaccine virus was analyzed. Flow cytometric analyses were used to determine percentual values of T and B cells in parallel to the yellow fever neutralizing antibody production. All lymphocyte subsets analyzed were augmented around the 30th post vaccination day, both for first-time vaccinees and re-vaccinees. CD3+ T cells increased from 30.8% (SE +/- 4%) to 61.15% (SE +/- 4.2%), CD4+ T cells from 22.4% (SE +/- 3.6%) to 39.17% (SE +/- 2%) with 43% of these cells corresponding to CD4+CD45RO+ T cells, CD8+ T cells from 15.2% (SE +/- 2.9%) to 27% (SE +/- 3%) with 70% corresponding to CD8+CD45RO+ T cells in first-time vaccinees. In re-vaccinees, the CD3+ T cells increased from 50.7% (SE +/- 3%) to 80% (SE +/- 2.3%), CD4+ T cells from 24.9% (SE +/- 1.4%) to 40% (SE +/- 3%) presenting a percentage of 95% CD4+CD45RO+ T cells, CD8+ T cells from 19.7% (SE +/- 1.8%) to 25% (SE +/- 2%). Among CD8+CD38+ T cells there could be observed an increase from 15 to 41.6% in first-time vaccinees and 20.7 to 62.6% in re-vaccinees. Regarding neutralizing antibodies, the re-vaccinees presented high titers even before re-vaccination. The levels of neutralizing antibodies of first-time vaccinees were similar to those presented by re-vaccinees at day 30 after vaccination, indicating the success of primary vaccination. Our data provide a basis for further studies on immunological behavior of the YF 17DD vaccine.
Santos
Ana Paula dos
AP
Laboratório de Tecnologia Imunológica, Bio-Manguinhos, Fiocruz, 21045-900 Rio de Janeiro, RJ, Brazil.
Bertho
Alvaro Luiz
AL
Dias
Daniela Capuzzo
DC
Santos
Jaciara Ramos
JR
Marcovistz
Rugimar
R
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000276:immunology; D016175:B-Lymphocyte Subsets / Q000276:immunology; D016516:CD4-CD8 Ratio; D005434:Flow Cytometry; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D016131:Lymphocyte Subsets / Q000276:immunology*; D008875:Middle Aged; D009500:Neutralization Tests; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013997:Time Factors; D014766:Viremia / Q000276:immunology; D015004:Yellow Fever / Q000276:immunology* / Q000517:prevention & control; D022341:Yellow Fever Vaccine / Q000276:immunology*; D015005:Yellow fever virus / Q000276:immunology*
D000914:Antibodies, Viral; D022341:Yellow Fever Vaccine